Patents

Oragenics receives small business grant, seeks patent for novel synthetic chemistry technology

Published in Health and Medicine Week, June 1st, 2006

Oragenics, Inc. (ONI) announced that it has been awarded an SBIR phase I grant from the National Science Foundation (NSF) for lantibiotic synthesis using the company's proprietary differentially protected orthogonal lanthionine technology (DPOLT).

Although the funded research will focus on the production of analogs from the potentially important class of antibiotics called lantibiotics, the technology has broader applications and may also be used for the cost-effective manufacture of a number of commercially important bioactive peptides.

The company has filed a U.S. patent application covering the intellectual property surrounding the DPOLT solid...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2006-06-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry